Zynex (ZYXI) Competitors

NeuroPace (NASDAQ:NPCE) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.

Which has stronger earnings & valuation, NPCE or ZYXI?

Zynex has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$79.91M	4.83	-$32.96M	-$0.95	-12.47
Zynex	$192.35M	0.37	$9.73M	$0.09	25.00

Which has more volatility & risk, NPCE or ZYXI?

NeuroPace has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Do analysts recommend NPCE or ZYXI?

NeuroPace presently has a consensus target price of $15.20, indicating a potential upside of 28.27%. Zynex has a consensus target price of $10.25, indicating a potential upside of 355.56%. Given Zynex's higher probable upside, analysts clearly believe Zynex is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Zynex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media favor NPCE or ZYXI?

In the previous week, Zynex had 32 more articles in the media than NeuroPace. MarketBeat recorded 36 mentions for Zynex and 4 mentions for NeuroPace. NeuroPace's average media sentiment score of 0.22 beat Zynex's score of 0.08 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zynex	3 Very Positive mention(s)	2 Positive mention(s)	26 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders believe in NPCE or ZYXI?

78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 22.2% of NeuroPace shares are owned by insiders. Comparatively, 52.1% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is NPCE or ZYXI more profitable?

Zynex has a net margin of 2.49% compared to NeuroPace's net margin of -36.74%. Zynex's return on equity of 13.05% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-36.74%	-205.41%	-28.29%
Zynex	2.49%	13.05%	3.78%

Does the MarketBeat Community believe in NPCE or ZYXI?

NeuroPace received 1 more outperform votes than Zynex when rated by MarketBeat users. Likewise, 60.78% of users gave NeuroPace an outperform vote while only 56.60% of users gave Zynex an outperform vote.

Company	Underperform	Outperform
NeuroPace	Outperform Votes 31 60.78%	Underperform Votes 20 39.22%
Zynex	Outperform Votes 30 56.60%	Underperform Votes 23 43.40%

Summary

Zynex beats NeuroPace on 10 of the 18 factors compared between the two stocks.